Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
ConditionHCC
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorChen Xiaoping
About this trial
Primary liver cancer is one of the most common malignant tumors in the world, and about 80%\~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). Radical surgery is the main method for patients with HCC to obtain long-term survival. However, the early recurrence rate of high-risk HCC is very high, which seriously affects the overall therapeutic effect.
Eligibility criteria
Qualifiers
Aged 18-75.
No previous local or systemic treatment for hepatocellular carcinoma.
Child-Pugh liver function score ≤ 7.
ECOG PS 0-1.
Disqualifiers
Pregnant and lactating women.
Suffering from a condition that interferes with the absorption, distribution, metabolism, or clearance of the study drug (e.g., severe vomiting, chronic diarrhea, intestinal obstruction, impaired absorption, etc.).
A history of gastrointestinal bleeding within the previous 4 weeks or a definite predisposition to gastrointestinal bleeding (e.g., known locally active ulcer lesions, fecal occult blood ++ or more, or gastroscopy if persistent fecal occult blood +) that has not been targeted, or other conditions that may have caused gastrointestinal bleeding (e.g., severe fundoplication/esophageal varices), as determined by the investigator.
Active infection.
Trial design
Treatments tested in this trial
- Hepatic arterial infusion chemotherapy
- Lenvatinib
- Tislelizumab
- Liver resection
- Tislelizumab
Treatment groups
160 Participants
are divided into 2 treatment groupsSponsors and collaborators
Chen Xiaoping
Lead sponsor
Tongji Hospital
Sponsor institution
Source ClinicalTrials.gov